Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Clin Gastroenterol Hepatol
; 11(11): 1503-10, 2013 Nov.
Article
em En
| MEDLINE
| ID: mdl-23707354
Palavras-chave
Cirrhosis; DAA; HCC; HCV; Health Care Costs; ICER; IL; Liver Disease; PR; Prevention; QALY; SVR; VHA; Veterans Health Administration; boc; boceprevir; direct-acting antiviral; hepatitis C virus; hepatocellular carcinoma; incremental cost-effectiveness ratio; interleukin; pegylated interferon-alfa and ribavirin; quality-adjusted life-year; sustained virologic response; tel; telaprevir
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Hepacivirus
/
Hepatite C Crônica
/
Saúde dos Veteranos
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Clin Gastroenterol Hepatol
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
2013
Tipo de documento:
Article